Descartes-15 / Cartesian Therapeutics - LARVOL DELTA

DC15-MM-01: Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=4 | Terminated | Sponsor: Cartesian Therapeutics | Trial completion date: Oct 2027 ➔ Nov 2025 | Active, not recruiting ➔ Terminated | Trial primary completion date: Dec 2026 ➔ Apr 2025; Phase 1 enrollment completed. Further clinical development terminated

Trial completion date • Trial primary completion date • Trial termination • Hematological Malignancies • Multiple Myeloma • Oncology

First-in-Human Phase 1 Clinical Trial of Descartes-15 Remains Ongoing (GlobeNewswire) - "The Phase 1 dose escalation trial of Cartesian’s next-generation, autologous anti-BCMA CAR-T cell therapy is designed to assess the safety and tolerability of outpatient Descartes-15 administration in patients with multiple myeloma."

Enrollment status • Multiple Myeloma

Preliminary Descartes-15 Safety Data (GlobeNewswire) - "The Company today reported results from the Phase 1 dose escalation trial designed to assess safety and tolerability of outpatient administration of Descartes-15 in patients with multiple myeloma. In this trial, no significant adverse events or dose-limiting toxicities were reported in any participants (n=3). The only Descartes-15-related adverse event was a grade 2 hypotension occurring after the first two infusions. Despite favorable safety data now in hand, Cartesian plans to pause the development of Descartes-15 to prioritize opportunities for Descartes-08..."

Discontinued • P1 data • Multiple Myeloma

DC15-MM-01: Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=4 | Active, not recruiting | Sponsor: Cartesian Therapeutics | Recruiting ➔ Active, not recruiting | N=41 ➔ 4

Enrollment change • Enrollment closed • Hematological Malignancies • Multiple Myeloma • Oncology

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) - "Dosing Continues in First-in-Human Phase 1 Clinical Trial of Descartes-15. The Phase 1 dose escalation trial of Cartesian’s next-generation, autologous anti-BCMA CAR-T cell therapy, is designed to assess the safety and tolerability of outpatient Descartes-15 administration in patients with multiple myeloma. Following the Phase 1 dose escalation trial, the Company expects to subsequently assess Descartes-15 in autoimmune indications."

Trial status • Immunology • Multiple Myeloma

Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15 (GlobeNewswire) - "Cartesian Therapeutics, Inc...announced that the first patient has been dosed in its first-in-human Phase 1 trial of Descartes-15, the Company’s next-generation autologous anti-B cell maturation antigen (BCMA) mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T)....The Phase 1 dose escalation trial (NCT06304636) will assess the safety and tolerability of outpatient Descartes-15 administration in patients with multiple myeloma."

Trial status • Hematological Malignancies • Multiple Myeloma • Oncology

Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing (GlobeNewswire) - "Descartes-08 for Pediatric Autoimmune Diseases: Cartesian plans to file an Investigational New Drug (IND) application for Descartes-08 in pediatric autoimmune disease indications by year-end 2024....Descartes-15 for Autoimmune Diseases: The Company expects to dose the first patient in its planned Phase 1 trial of Descartes-15 in the second half of 2024.....Completed $130 Million Private Placement Equity Financing...Cartesian announced a private investment in public equity (PIPE) financing, which included participation from both new and existing investors, resulting in gross proceeds of approximately $130.0 million....Cartesian expects to use the net proceeds to advance and expand its autoimmune pipeline through continued development of Descartes-08 for SLE, Descartes-15 for autoimmune diseases."

Financing • IND • New P1 trial • Immunology

DC15-MM-01: Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=41 | Recruiting | Sponsor: Cartesian Therapeutics | Initiation date: Mar 2024 ➔ Jun 2024

Trial initiation date • Hematological Malignancies • Multiple Myeloma • Oncology

DC15-MM-01: Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=41 | Recruiting | Sponsor: Cartesian Therapeutics

New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology

Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity (GlobeNewswire) - "Program Updates and Anticipated 2024 Milestones....The Company today announced that the U.S. FDA has cleared its IND application for Descartes-15. Planning for a first-in-human Phase 1 dose escalation study is underway. The study will be designed to assess the safety and tolerability of outpatient Descartes-15 administration in patients with multiple myeloma. The Company expects to subsequently assess Descartes-15 in autoimmune indications."

IND • New P1 trial • Hematological Malignancies • Immunology • Multiple Myeloma • Oncology